Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B: Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008, 3: 1526-1533. 10.2215/CJN.00950208.
Article
PubMed
PubMed Central
Google Scholar
Chonchol M: Neutrophil dysfunction and infection in end-stage renal disease. Semin Dial. 2006, 19: 291-296. 10.1111/j.1525-139X.2006.00175.x.
Article
PubMed
Google Scholar
Porto G, DeSousa M: Iron overload and immunity. Worl J Gastroenterol. 2007, 13: 4707-4715.
Article
CAS
Google Scholar
Deicher R, Ziai F, Cohen G, Müllner M, Hörl WH: High dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int. 2003, 64: 728-736. 10.1046/j.1523-1755.2003.00125.x.
Article
CAS
PubMed
Google Scholar
Guo D, Jaber BL, Lee S, Perianayagam MC, King AJ, Pereira BJ, Balakrishnan VS: Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol. 2002, 58: 134-142.
Article
CAS
PubMed
Google Scholar
Eleftheriadis T, Kartsios C, Yiannaki E, Antoniadi G, Kazila P, Pliakos K, Liakopoulos V, Markala D: Decreased CD3+CD16+ natural killer-like T-cell percentage and zeta-chain expression accompany chronic inflammation in hemodialysis patients. Nephrology. 2009, 14: 471-5. 10.1111/j.1440-1797.2008.01041.x.
Article
CAS
PubMed
Google Scholar
Vacher-Coponat H, Brunet C, Lyonnet L, Bonnet E, Loundou A, Sampol J, Moal V, Dussol B, Brunet P, Berland Y, Dignat-George F, Paul P: Natural killer cell alterations correlate with loss of renal function and dialysis duration in hemodialysis patients. Nephrol Dial Transplant. 2008, 1406-14.
Google Scholar
Liu JH, Liu YL, Lin HH, Yang YF, Kuo HL, Lin PW, Huang CC: Intravenous iron attenuates postvaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy. Int J Clin Pract. 2009, 63: 387-93. 10.1111/j.1742-1241.2008.01732.x.
Article
CAS
PubMed
Google Scholar
Zager RA: Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol. 2006, 1 (Suppl 1): S24-31. 10.2215/CJN.01410406.
Article
CAS
PubMed
Google Scholar
Pai AB, Harford A, Boyd AV, McQuade C, Norenberg JP, Zager P: Comparison of oxidative stress markers in hemodialysis patients following administration of iron dextran, sodium ferric gluconate and iron sucrose. Pharmacotherapy. 2007, 27: 343-350. 10.1592/phco.27.3.343.
Article
CAS
PubMed
Google Scholar
Djeha A, Brock JH: Uptake and intracellular handling of iron from transferrin and iron chelates by mitogen stimulated mouse lymphocytes. Biochem Biophys Acta. 1992, 1133: 147-52. 10.1016/0167-4889(92)90062-G.
Article
CAS
PubMed
Google Scholar
Carvalho GS, deSousa M: Iron exerts a specific inhibitory effect on CD2 expression of human PBL. Immunol Lett. 1988, 19: 163-167. 10.1016/0165-2478(88)90137-X.
Article
CAS
PubMed
Google Scholar
LaFrance JP, Rahme E, Lelorier J, Iqbal S: Vascular access-related infections: definitions, incidence rates and risk factors. Am J Kidney Dis. 2008, 52: 982-983. 10.1053/j.ajkd.2008.06.014.
Article
PubMed
Google Scholar
De Vecchi AF, Novembrino C, Lonati S, Ippolito S, Bamonti F: Two different modalities of iron gluconate iv administration: effects on iron, oxidative and inflammatory status in peritoneal dialysis patients. 2007, 22: 1709-1713.
Google Scholar
Tenopoulou M, Doulias PT, Barbouti A, Brunk U, Galaris D: Role of compartmentalized redox-active iron in hydrogen peroxide-induced DNA damage and apopotosis. Biochem J. 2005, 387: 703-710. 10.1042/BJ20041650.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zager RA, Johnson AC, Hanson SY: Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int. 2004, 66: 144-156. 10.1111/j.1523-1755.2004.00716.x.
Article
CAS
PubMed
Google Scholar
Degasperi GR, Castilho RF, Vercesi AE: High susceptibility of activated lymphocytes to oxidative stress-induced cell death. An Acad Bras Cienc. 2008, 80: 137-48.
Article
CAS
PubMed
Google Scholar
Rao M, Guo D, Jaber BL, Sundaram S, Cendoroglo M, King AJ, Pereira BJ, Balakrishnan VS, HEMO Study Group: Dialyzer membrane type and reuse practice influence polymorphonuclear leukocyte function in hemodialysis patients. Kidney Int. 2004, 65: 682-91. 10.1111/j.1523-1755.2004.00429.x.
Article
PubMed
Google Scholar
Pai AB, Raj D, McQuade C, Olp J, Hicks PP, Conner TA: Non-transferrin Bound Iron (NTBI), Cytokine Activation and Intracellular Reactive Oxygen Species Generation in hemodialysis (HD) Patients Receiving Iron Dextran (ID) or Iron Sucrose (IS). J Am Soc Nephrol. 2008, 19: 263A-
Google Scholar
Lim PS, Wei YH, Yu YL, Kho B: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant. 1999, 14 (11): 2680-7. 10.1093/ndt/14.11.2680.
Article
CAS
PubMed
Google Scholar
Rogacev K, Ziegelin M, Ulrich C, Seiler S, Girndt M, Fliser D, Heine GH: Haemodialysis-induced transient CD16+ monocytopenia and cardiovascular outcome. Nephrol Dial Transplant. 2009, 24: 3480-3486. 10.1093/ndt/gfp287.
Article
CAS
PubMed
Google Scholar